Adagene INC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ

1 Apr 2026

ADAG

Adagene INC

20-F: Adagene Narrows 2025 Net Loss, Boosted by Strategic Collaborations

Adagene Inc. reported a significantly reduced net loss of $17.6 million in 2025, driven by increased licensing and collaboration revenue and focused R&D efforts on its lead candidate, ADG126.

NASDAQ

24 Mar 2025

ADAG

Adagene INC

20-F: Adagene Inc. Files 20-F Report, Highlights Clinical Pipeline and Financial Results for 2024

Adagene Inc.'s 20-F filing details the company's clinical pipeline progress and financial results for the year ended December 31, 2024.

NASDAQ

29 Mar 2024

ADAG

Adagene INC

20-F: Adagene Inc. Files 2023 Annual Report on Form 20-F, Details Financial Performance and Corporate Governance

Adagene Inc.'s 2023 Form 20-F filing includes audited financial statements, auditor consent, and details on share capital, executive compensation, and corporate governance.